DnB Asset Management AS Has $8.14 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

DnB Asset Management AS grew its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 381,232 shares of the company's stock after buying an additional 22,590 shares during the quarter. DnB Asset Management AS's holdings in Kenvue were worth $8,139,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Townsquare Capital LLC increased its position in Kenvue by 25.3% in the 3rd quarter. Townsquare Capital LLC now owns 52,713 shares of the company's stock valued at $1,219,000 after acquiring an additional 10,629 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Kenvue by 30.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 9,992,933 shares of the company's stock valued at $231,137,000 after purchasing an additional 2,316,443 shares during the last quarter. White Knight Strategic Wealth Advisors LLC bought a new stake in shares of Kenvue during the third quarter valued at approximately $256,000. Alerus Financial NA increased its holdings in shares of Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company's stock valued at $4,426,000 after purchasing an additional 491 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in Kenvue in the 3rd quarter worth approximately $360,000. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

NYSE:KVUE traded down $0.10 during trading hours on Thursday, reaching $23.77. 3,958,438 shares of the company were exchanged, compared to its average volume of 16,692,091. The business has a 50 day moving average of $22.50 and a 200 day moving average of $22.47. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $45.43 billion, a P/E ratio of 44.85, a P/E/G ratio of 2.62 and a beta of 1.25.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.45%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is presently 154.72%.

Analyst Ratings Changes

Several research firms have recently commented on KVUE. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Kenvue presently has a consensus rating of "Hold" and an average target price of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.